Pathogen-reduced platelets for the prevention of bleeding.

CONCLUSIONS: Findings from this review were based on 12 trials, and of the 1981 participants who received a platelet transfusion only 44 did not have a haematological or oncological diagnosis.In people with haematological or oncological disorders who are thrombocytopenic due to their disease or its treatment, we found high-quality evidence that pathogen-reduced platelet transfusions increase the risk of platelet refractoriness and the platelet transfusion requirement. We found moderate-quality evidence that pathogen-reduced platelet transfusions do not affect all-cause mortality, the risk of clinically significant or severe bleeding, or the risk of a serious adverse event. There was insufficient evidence for people with other diagnoses.All three ongoing trials are in adults (planned recruitment 1375 participants) with a haematological or oncological diagnosis. PMID: 28756627 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28756627?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - July 30, 2017 Category: General Medicine Authors: Estcourt LJ, Malouf R, Hopewell S, Trivella M, Doree C, Stanworth SJ, Murphy MF Tags: Cochrane Database Syst Rev Source Type: research